Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Ebatid IV infusion

Dexa Medica

Ingredients in every 100 ml

Eptifibatide 75 mg

Each package contains

1 bottle of 100 ml

Dosage form

IV infusion

Dosage formIntravenous infusion

Flavour

None

W.H.O. classification

B01A
B01A

A.T.C. Level 1

Anatomical Main group

B - Blood and blood forming organs
B01A

A.T.C. Level 2

Therapeutic subgroup

B01 - Antithrombotic Agents
B01A

A.T.C. Level 3

Pharmacological subgroup

B01A - Antithrombotic Agents

Available in

Indonesia

Warnings

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Pregnancy

CONSULT YOUR DOCTORSafety of this item for use during pregnancy has not been established. Please consult your doctor.

Lactation

CONSULT YOUR DOCTORSafety of this item for use during lactation has not been established. Please consult your doctor.

Indication

For the treatment of patients with acute coronary syndrome
For the treatment of patients with acute coronary syndrome (Unstable Angina (UA)/Non-Q Wave Myocardial Infarction (NQMI)), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, eptifibatide has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction.
For the treatment of patients undergoing PCI, including those undergoing intracoronary stenting
In this setting, eptifibatide has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention.

Dosage

18 YEARS OLD AND ABOVE
-- Acute coronary syndrome (Unstable angina or Non-Q-wave myocardial infarction)
a). with creatinine clearance ≥ 50 ml/minute:
Intravenous bolus 180 mcg/kg, followed by continuous infusion 2.0 mcg/kg/minute until hospital discharge or initiation of coronary artery bypass graft, up to 72 hours. Patients weighing more than 121 kg should receive a maximum bolus of 22.6 mg followed by a maximum infusion rate of 15 mg per hour.

b). with creatinine clearance ≥30 – <50 ml/minute:
Intravenous bolus 180 mcg/kg, followed by continuous infusion 1.0 mcg/kg/minute until hospital discharge or initiation of coronary artery bypass graft, up to 72 hours. Patients weighing more than 121 kg should receive a maximum bolus of 22.6 mg followed by a maximum infusion rate of 7.5 mg per hour.

-- Patients undergoing Percutaneous Coronary Intervention (PCI)
a). with creatinine clearance ≥ 50 ml/minute:
Intravenous bolus 180 mcg/kg before PCI, followed by continuous infusion 2.0 mcg/kg/minute and a second 180 mcg/kg bolus, 10 minutes after the first bolus injection. Simultaneously with the first bolus, a continuous infusion should be started at a dose of 2.0 mcg/kg/minute. Infusion should be continued until hospital discharge or maximum of 18-24 hours post-PCI, whichever comes first. A minimum of 12 hours of infusion is recommended.

b). with creatinine clearance ≥30 – <50 ml/minute:
Intravenous bolus of 180 mcg/kg administered immediately before initiation of the procedure, followed by a second 180 mcg/kg bolus administered 10 minutes after the first bolus injection. Simultaneously with the first bolus dose, a continuous infusion should be started at a dose of 1.0 mcg/kg/minute. Continue the infusion until hospital discharge or up to a maximum of 18-24 hours post-PCI. A minimum of 12 hours of infusion is recommended.

Eptifibatide is to be administered by volume according to patient weight.

0 TO 18 YEARS OLD
Safety and effectiveness have not been studied.

Eptifibatide is to be administered by volume according to patient weight.

65 YEARS OLD AND ABOVE
No dose adjustment was made for elderly patients.

Eptifibatide is to be administered by volume according to patient weight.